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Abstract
Hereditary haemorrhagic telangiectasia (HHT; Osler–Weber–Rendu disease) is an autosomal
dominant vascular disease characterized by nosebleeds, mucocutaneous telangiectases, visceral
arteriovenous malformations (AVM) and a first-degree relative with HHT. Diagnosis is definite if
three or four criteria are present. This case report describes a 19-year-old male with incidentally
detected polycythaemia and an associated soft-tissue opacity over the left lower lobe on his
frontal chest radiogram. He had experienced dyspnoea on exertion since infancy and clubbing at
physical examination. Polycythaemia vera, chronic obstructive pulmonary disease, sleep apnoea
and cyanotic congenital heart disease were excluded. Chest computed tomography (CT) was
initially refused by the patient, but 3 years later he presented with severe epistaxis. Considering
the unvarying soft tissue mass and erythrocytosis, an HHT-associated pulmonary AVM (PAVM)
was eventually confirmed by chest CT. A pathogenic family-specific ENG c.817-2 A>C mutation
was detected in the patient. The large PAVM was successfully treated using AMPLATZERTM
vascular plug embolization. A combination of the multisystemic nature of his symptoms, the
age-related penetrance of HHT symptoms and insufficient patient compliance delayed the diag-
nosis of HHT in this current case.
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Introduction
Hereditary haemorrhagic telangiectasia
(HHT; Osler–Weber–Rendu disease) is an
autosomal dominant vascular disease
described by the four Curacao criteria: (i)
spontaneous and recurrent nosebleeds (with
approximate frequency of 90–95%; mean
age at onset of 12 years); (ii) multiple telan-
giectases at characteristic sites such as the
lips, oral cavity, fingers and nose (90%; 30
years); (iii) visceral lesions as gastrointesti-
nal telangiectasia (20–80%) and pulmonary
(30–50%), hepatic (32–48%) and cerebral
or spinal (23%) arteriovenous malforma-
tions (AVM); and (iv) family history with
a first-degree relative with HHT.1 Diagnosis
is definite if three or four criteria are pre-
sent, possible if two criteria are present and
unlikely if fewer than two criteria are
present.1 The worldwide prevalence of
HHT is estimated to be 1:5000–1:10 000.2
Approximately 85% of HHT cases have
heterozygous family-specific mutations
either in the ENG (encodes endoglin) or
the ACVRL1 (encodes activin receptor-like
kinase 1) genes, causing HHT type 1 and 2,
respectively.3 These genes encode proteins
belonging to the transforming growth
factor-beta (TGF)-b superfamily.2 While
AVMs are considered to be congenital,
HHT shows age-related penetrance regard-
ing epistaxis and telangiectases.2 As a con-
sequence, the sensitivity of the Curacao
criteria might be insufficient in children
and young adults, emphasizing the signifi-
cance of genetic testing in these age groups.4
Case report
In March 2011, a 19-year-old non-smoking
male with a prior medical history of trau-
matic left rib 8 and 9 fractures was referred
to the Department of Otorhinolaryngology,
Ferenc Markhot County Hospital, Eger,
Hungary with polycythaemia (haemoglobin
20.5 g/dl), which was detected as part of a
routine complete blood count test preceding
a blood donation. He reported dyspnoea on
exertion since his infancy and a negative
family history. On physical examination,
clubbing was observed. At resting (supine)
pulse oximetry, SaO2 was 91%. Cyanotic
congenital heart disease was excluded by
transthoracic echocardiography, while
transoesophageal echocardiography was
refused by the patient. Frontal chest radi-
ography showed a 3  4 cm oval soft-tissue
opacity projected over the left lower lobe of
the lung. A pulmonologist excluded both
tuberculosis (by an interferon gamma
release assay) and chronic obstructive pul-
monary disease (COPD); and referred the
patient for computed tomography (CT),
but he did not attend for the scheduled
examination.
Although polycythaemia vera was
excluded by the World Health
Organization 2008 diagnostic criteria valid
at that time (with no JAK2 V617F and exon
12 mutations; elevated erythropoietin
level),5 antiplatelet therapy (100 mg aspirin
administered orally, daily in the subsequent
6 months) was initiated and the patient
underwent a series of venesections.
Despite all of these interventions, the
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polycythaemia persisted (with haemoglobin
18.4–20.0 g/dl) and in November 2012, the
patient was lost to follow-up.
In April 2014, the patient presented again
to the Department of Otorhinolaryngology,
Ferenc Markhot County Hospital, Eger,
Hungary with episodic epistaxis in the pre-
ceding 5 days, requiring both unilateral
anterior and posterior nasal packings. He
had never suffered from nosebleeds before.
On frontal chest radiogram, the aforemen-
tioned soft-tissue opacity was detected in an
unvarying size and location (Figure 1) as
compared with that observed 3 years previ-
ously. A pulmonary AVM (PAVM) result-
ing in a right-to-left shunt was suspected as a
cause for secondary erythrocytosis, and
eventually, the patient underwent the recom-
mended chest CT. After the administration
of intravenous iodinated contrast medium,
a 52 42 36mmmass showing an homog-
enous enhancement in the early arterial
phase was detected (Figure 2a), with clearly
identifiable feeding and draining vessels in
the coronal plane images (Figure 2b).
Figure 1. Frontal chest radiogram in April 2014 of
a 19-year-old male with incidentally detected poly-
cythaemia shows a 3 x 4 cm oval soft-tissue opacity
projected over the left lower lobe. Reviewing the
film, there were two undocumented prominences
(arrows) medial to the mass.
Figure 2. (a) Axial contrast-enhanced computed tomography image on a mediastinal window setting of
a 19-year-old male with incidentally detected polycythaemia demonstrated a 52  42  36 mm mass in
the anterior basal segment of the left lung showing homogenous enhancement in the early arterial phase.
(b) A contrast-enhanced coronal plane image shows an identifiable feeding vessel (arrow) originating from
the lower lobe branch of the left pulmonary artery and a draining vessel (dotted arrow) joining the inferior
pulmonary vein.
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Epistaxis and PAVM suggested HHT,
although epistaxis was not recurrent and
the patient had no telangiectases at the
characteristic sites. Hepatic AVMs were
excluded by the simultaneous upper
abdominal CT scan. The patient was
offered the opportunity to investigate the
possibility of cerebral AVMs by undertak-
ing magnetic resonance imaging, but again,
he refused the examination. Since the sys-
tematic screening of HHT (including phys-
ical examination, AVM screening and
genetic test) was already under way at that
time in the primary care clinic of our set-
ting, enquiries based on the surnames of
individuals in the patient’s family identified
his maternal grandfather as a known defi-
nite HHT patient (Figure 3). The patient’s
mother refused the HHT screening (she has
no nosebleeds and telangiectases according
to information provided by the grandfather
and the patient). Thus, adhering strictly to
the diagnostic criteria (his epistaxis was not
recurrent), the patient was diagnosed with
possible HHT (PAVMþ family history),
confirmed by the detection of the family-
specific pathogenic ENG c.817-2 A>C
splice-site mutation.6
Finally, following subsequent compli-
ance problems, the large pulmonary AVM
was successfully treated using
AMPLATZERTM vascular plug (Abbott
Laboratories, Abbott Park, IL, USA)
embolization in October 2016 (Figure 4).
The patient has not been observed since
his post-embolization CT, but according
to his family practitioner, he is presently
asymptomatic.
The HHT investigation protocol was
approved by the Institutional Research
Ethics Board of the Department of
Otorhinolaryngology, Ferenc Markhot
County Hospital, Eger, Hungary (no.
IKEB/HHT-FOG Oszta´ly/2013/2).
Written informed consent for patient infor-
mation and images to be published was pro-
vided by the patient.
Discussion
In this current case, erythrocytosis was
considered to be a secondary,
hypoxaemia-driven form, which might
have been long-standing, based upon the
dyspnoea that had been apparent on exer-
tion since infancy and the signs of clubbing.
After the exclusion of COPD, sleep apnoea
and cyanotic congenital heart disease, the
co-existence of hypoxaemia, erythrocytosis
Figure 3. The proximate branch of a large
hereditary haemorrhagic telangiectasia (HHT)
family with an ENG c.817-2 A>C mutation. The
current patient, a 19-year-old male with incidentally
detected polycythaemia, is marked with an arrow
(IV.2.). Filled individuals are affected, either by car-
rying the mutation and/or having definite HHT. In
the upper left index †¼ definite HHT, ‡¼ possible
HHT, *¼ deceased or unavailable patient with epi-
staxis and/or telangiectases by hearsay. In the upper
right index M¼ family-specific ENG mutation,
u¼ patient unavailable for family screening. The
patient’s 66-year-old maternal grandfather (II.1.)
was diagnosed by the systematic screening of HHT
patients in the primary care area of our setting. The
patient’s 44-year-old mother (III.2.) refused the
HHT screening, but, according to the HHT inheri-
tance, she must be a mutation carrier.
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and the unknown pulmonary mass should
have suggested a PAVM as the cause of
right-to-left vascular shunting.7 Reviewing
the frontal chest radiogram, there were
two undocumented prominences medial to
the mass, corresponding to vascular mark-
ings (Figure 1). The radiologist was pre-
sumably not aware of the detailed medical
history, and furthermore, more common
diseases (including malignant neoplasms)
exist with a similar plain film appearance.8
Since CT, the reference standard investiga-
tion for diagnosing PAVMs, was eventually
performed (Figure 2), the diagnosis of the
mass as a PAVM was unequivocal.
Pulmonary AVMs are abnormal dilated
vessels that provide direct communication
between the pulmonary arteries and veins,
resulting in a right-to-left shunt and bypass-
ing the pulmonary capillary bed.8,9 Their
prevalence is 1:2600, with a mild female pre-
dominance (1:1.5–1.8).10 Upon radiological
features, they are classified as simple (an
aneurysmal sac with a single feeder artery
and one or more draining veins, like in this
current case) or complex (vascularized by
more than one artery and multiple veins).
Both forms might be single or multiple,
with a predilection in the lower lobes.
Diffuse forms involving one or more
segments or even an entire lobe and telan-
giectatic forms are extremely rare. A variety
of vascular (true and false aneurysms,
pulmonary varices, pulmonary artery col-
laterals) and non-vascular (bronchocoeles,
primary or metastatic tumours) might
mimic PAVMs.8
Although the majority of PAVMs are
asymptomatic and diagnosed by incidental
imaging, they are associated with serious
acute and chronic morbidity and mortality,
related to right-to-left shunting (cyanosis,
dyspnoea), bypassing the pulmonary capil-
lary filtration (paradoxical embolic stroke,
cerebral abscesses, transient cerebral ischae-
mic attacks, myocardial infarction, infec-
tions) and haemorrhage (haemoptysis,
haemothorax, maternal death in pregnan-
cy).11 Beyond some rare forms (sporadic,
surgical cavo-pulmonary shunts, trauma),
Figure 4. (a) Pre-embolization left pulmonary catheter arteriography from femoral venous access dem-
onstrating a simple arteriovenous malformation (AVM), the enlargement of feeding vessels and early venous
return. (b) Post-embolization pulmonary arteriogram shows complete occlusion of the lesion, without
additional feeders and unsuspected new or remaining pulmonary AVMs. The photo was made between the
opening and the detachment of the 14 mm AMPLATZERTM vascular plug (arrow).
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approximately 70% of PAVM cases are
associated with HHT, and conversely,
15–50% of HHT patients (with HHT1 pre-
dominance) will develop PAVM.12 Solid
organ AVMs are usually congenital in
HHT, starting out small, at-near capillary-
like dimensions.3,13 Detectable PAVMs are
rare in the first decade of life and usually
complete development by early adulthood,
although they might enlarge in number and
size later on in pregnancy or following alter-
ations in pulmonary circulation (including
embolization of existing PAVMs).9 In this
current case, the first chest radiogram was
made at the age of 19, though the mild com-
plaints in the medical history suggest an ear-
lier onset at infancy.
Epistaxis, the earliest and most common
clinical symptom of HHT, has an overall
penetrance of 50% by 10 years and
80–95% by 21 years.12 Mucosal and
dermal telangiectases usually appear in the
third decade of life.14 This current patient
showed none of these symptoms at his first
admission, and furthermore, he was not
aware of his family history of HHT.
At that time, only a promptly diagnosed
PAVM and a carefully recorded family his-
tory might have been suggestive of the
underlying HHT. This should have been
confirmed by the detection of the pathogen-
ic family-specific mutation in the patient.
Although not a diagnostic criterion, the sig-
nificance of genetic screening in each avail-
able at-risk individual in HHT families
must be emphasized.4
In patients with PAVMs of a size ame-
nable to treatment (feeding artery diameter
above 2–3 mm), embolization with vascular
plugs is the first-line therapy, irrespective of
symptoms.10 Surgical resection is reserved
for selected cases (e.g. a proportion of com-
plex, diffuse or multiple AVMs, symptom-
atic lesions with feeders too small for
embolization, persistent neurological symp-
toms despite embolization). Long-term
follow-up is needed either by CT or on a
clinical basis to reduce radiation expo-
sure.4,11 Explanations for the recurrence of
PAVM might be persistent small PAVMs
that would grow due to the altered blood
flow or continuous defects in the signalling
pathway of the TGF-b/bone morphogenic
protein superfamily leading to angiodysgen-
esis.15 Patients with diagnosed PAVMs
need judicious dental hygiene and antibiotic
prophylaxis prior to dental and surgical
procedures to reduce the rate of cerebral
abscesses.9 As secondary erythrocytosis is
an adaptive response to hypoxaemia in
PAVM, venesection is not recommended,
unless the patient shows hyperviscos-
ity symptoms.11
This current case has been presented to
draw attention to the potential pitfalls of
delaying the diagnosis of HHT: (i) HHT is
a rare disease; (ii) it has an age-related pen-
etrance regarding the most common symp-
toms of epistaxis and telangiectases; (iii)
congenital internal AVMs are most often
asymptomatic, until diagnosed incidentally
or by their life-threatening complications;
(iv) especially young asymptomatic or
mildly symptomatic individuals might
therefore be noncompliant; (v) each disci-
pline (haematology, pulmonology, cardiol-
ogy, radiology and otorhinolaryngology in
this current case) might identify the symp-
toms of a multisystemic disease one by one,
but without realising that they are linked by
the underlying HHT syndrome.
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